Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
influenza vaccine
Manufacturing
Its future murky, CSL Seqirus opens $1B vax plant in Australia
CSL Seqirus has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom facility in Melbourne.
Joseph Keenan
Dec 9, 2025 9:08am
FDA to take harder look at coadministration of certain vaccines
Sep 4, 2025 10:40am
University of Michigan seeks damages over AZ's FluMist sales
Aug 29, 2025 10:15am
HHS signs off on recommendation to ban thimerosal from vaccines
Jul 23, 2025 3:03pm
CDC panel recommends against use of thimerosal in flu vaccines
Jun 26, 2025 4:47pm
AZ's FluMist wins FDA nod as first self-administered flu vaccine
Sep 20, 2024 3:24pm